| Hannah W Jones, CRNA | |
|
1444 Peterman Dr, Alexandria, LA 71301-3432 | |
| (318) 442-5399 | |
| (318) 442-1586 |
| Full Name | Hannah W Jones |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 12 Years |
| Location | 1444 Peterman Dr, Alexandria, Louisiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043556582 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | 132060 (Louisiana) | Secondary |
| 367500000X | Nurse Anesthetist, Certified Registered | AP07161 (Louisiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Christus St Frances Cabrini Hospital | Alexandria, LA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mid-louisiana Anesthesia Consultants, Apmc | 3971408733 | 53 |
News Archive
Positive progression-free survival results from the RADIANT-4 and NETTER-1 trials extend the armamentarium for physicians treating patients with neuroendocrine tumours.
Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that it has completed enrollment of a randomized Phase 2 study of its lead candidate, CRLX101, in advanced non-small cell lung cancer (NSCLC). The company also announced that it has dosed the first patient in a second tumor type.
One of today's urgent health threats is antibiotic resistance, caused by inappropriate prescription and use of antibiotics, and — according to the Centers for Disease Control and Prevention — approximately 50 percent of all antibiotics prescribed in the United States are unnecessary or inappropriate, with many of them prescribed in inpatient settings.
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene, a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that enrollment and treatment of patients in a Phase 1b clinical trial has been initiated to evaluate JX-594 in patients with advanced metastatic, refractory colorectal cancer (CRC).
In 1972, just 18 days after he was selected to run for vice president with Democratic Sen. George McGovern, Thomas Eagleton was forced off the ticket.
› Verified 8 days ago
| Entity Name | Mid-louisiana Anesthesia Consultants, Apmc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205888914 PECOS PAC ID: 3971408733 Enrollment ID: O20031204000583 |
News Archive
Positive progression-free survival results from the RADIANT-4 and NETTER-1 trials extend the armamentarium for physicians treating patients with neuroendocrine tumours.
Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that it has completed enrollment of a randomized Phase 2 study of its lead candidate, CRLX101, in advanced non-small cell lung cancer (NSCLC). The company also announced that it has dosed the first patient in a second tumor type.
One of today's urgent health threats is antibiotic resistance, caused by inappropriate prescription and use of antibiotics, and — according to the Centers for Disease Control and Prevention — approximately 50 percent of all antibiotics prescribed in the United States are unnecessary or inappropriate, with many of them prescribed in inpatient settings.
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene, a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that enrollment and treatment of patients in a Phase 1b clinical trial has been initiated to evaluate JX-594 in patients with advanced metastatic, refractory colorectal cancer (CRC).
In 1972, just 18 days after he was selected to run for vice president with Democratic Sen. George McGovern, Thomas Eagleton was forced off the ticket.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Hannah W Jones, CRNA Po Box 5887, Alexandria, LA 71307-5887 Ph: (318) 442-5399 | Hannah W Jones, CRNA 1444 Peterman Dr, Alexandria, LA 71301-3432 Ph: (318) 442-5399 |
News Archive
Positive progression-free survival results from the RADIANT-4 and NETTER-1 trials extend the armamentarium for physicians treating patients with neuroendocrine tumours.
Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that it has completed enrollment of a randomized Phase 2 study of its lead candidate, CRLX101, in advanced non-small cell lung cancer (NSCLC). The company also announced that it has dosed the first patient in a second tumor type.
One of today's urgent health threats is antibiotic resistance, caused by inappropriate prescription and use of antibiotics, and — according to the Centers for Disease Control and Prevention — approximately 50 percent of all antibiotics prescribed in the United States are unnecessary or inappropriate, with many of them prescribed in inpatient settings.
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene, a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that enrollment and treatment of patients in a Phase 1b clinical trial has been initiated to evaluate JX-594 in patients with advanced metastatic, refractory colorectal cancer (CRC).
In 1972, just 18 days after he was selected to run for vice president with Democratic Sen. George McGovern, Thomas Eagleton was forced off the ticket.
› Verified 8 days ago
Elizabeth A Cole, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1444 Peterman Dr, Alexandria, LA 71301 Phone: 318-442-5399 Fax: 318-442-1586 | |
Clinton D Sellers, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 211 4th St # 30135, Alexandria, LA 71301 Phone: 318-448-4440 Fax: 318-473-4340 | |
Jeffery E Thomas, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 211 4th St, Alexandria, LA 71301 Phone: 318-769-3000 | |
Todd C Antony, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 211 4th St, Alexandria, LA 71301 Phone: 318-473-3000 | |
Donna K Moreau, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1444 Peterman Dr, Alexandria, LA 71301 Phone: 318-442-5399 Fax: 318-442-1586 | |
Rene Dejean, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1444 Peterman Dr, Alexandria, LA 71301 Phone: 318-442-5399 Fax: 318-442-1586 | |
Matthew J Meynard, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1444 Peterman Dr, Alexandria, LA 71301 Phone: 318-442-5399 Fax: 318-442-1586 |